vTv Therapeutics Inc Dossier
Qualitative Analysis
Business overview
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company focused on the discovery and clinical development of orally administered small molecule drug candidates. The company's primary therapeutic focus is on metabolic diseases, particularly type 1 diabetes (T1D). Its lead clinical asset is cadisegliatin (also known as TTP399), a novel, potential first-in-class, liver-selective glucokinase activator (GKA). Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) as an oral adjunctive therapy to insulin for T1D. Beyond its lead program, vTv maintains a pipeline of earlier-stage and out-licensed assets, including HPP737 (a PDE4 inhibitor) and other small molecules targeting chronic diseases.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the Phase 3 CATT1 trial evaluating cadisegliatin as a liver-selective glucokinase activator adjunctive therapy to insulin. The trial protocol was amended to shorten the duration from 12 to 6 months to expedite the timeline to topline data.
Expected impact: Establish cadisegliatin as a first-in-class oral adjunctive therapy that reduces hypoglycemic events and improves glycemic control in T1D patients.
Developing cadisegliatin for type 2 diabetes in collaboration with M42's Insights Research Organization & Solutions (IROS). A Phase 2 clinical study protocol was submitted to the Department of Health Abu Dhabi.
Expected impact: Broaden the therapeutic indications of cadisegliatin to address the larger type 2 diabetes patient population.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Newsoara exclusive global rights to vTv's highly selective PDE4 inhibitor, HPP737, for the treatment of inflammatory diseases, providing non-dilutive capital to support vTv's core focus on cadisegliatin.
Terms: $20.0 million upfront payment received in February 2026, with eligibility for up to $50.0 million in development milestones, up to $65.0 million in sales milestones, and tiered royalties on net sales.
Collaborating to evaluate cadisegliatin in a Phase 2 clinical study for type 2 diabetes in the United Arab Emirates.
Terms: M42 is funding the clinical study, while vTv Therapeutics serves as the regulatory sponsor.